Department of Pneumology, University Medicine Essen - Ruhrlandklinik, West German Lung Center, University Duisburg-Essen, Duisburg, Germany.
Faculty of Sleep and Telemedicine, University Medicine Essen - Ruhrlandklinik, West German Lung Center, University Duisburg-Essen, Tueschener Weg 40, 45239, Essen, Germany.
Eur Arch Otorhinolaryngol. 2023 Oct;280(10):4627-4639. doi: 10.1007/s00405-023-08062-1. Epub 2023 Jun 24.
Hypoglossal nerve stimulation (HNS) has recently been introduced as an alternative treatment for patients with OSA. A large number of studies have demonstrated substantial changes in OSA with this therapy by reducing respiratory events and improving symptoms such as daytime sleepiness and quality of life. The objective of this review was to conduct a systematic review and meta-analysis to evaluate patient-reported outcomes and experience with HNS therapy.
A systematic literature search of MEDLINE, Cochrane, and Web of Science was performed to identify randomized controlled and observational studies reporting subjective outcomes with different HNS systems in patients with OSA. Abstracts of 406 articles were screened and a subset of 55 articles were reviewed for eligibility. Risk of bias was assessed using the ROBINS-I tool. Meta-analysis using RevMan was performed when > 2 studies were identified that reported data on a specific outcome.
Thirty-four publications reporting data on 3785 patients with a mean follow-up of 11.8 ± 12.2 months were identified and included in the meta-analysis. The analysis revealed a pooled effect of 4.59 points improvement in daytime sleepiness as measured by the ESS questionnaire (Z = 42.82, p < .001), 2.84 points improvement in daytime functioning as measured by the FOSQ score (Z = 28.38, p < .001), and 1.77 points improvement in sleep quality as measured by the PSQI questionnaire (Z = 2.53, p = .010). Patient-reported experience was consistently positive and revealed additional relevant aspects from this perspective.
HNS therapy significantly improves quality of life in patients with OSA and reliably produces clinically meaningful effects on daytime sleepiness, daytime functioning, and sleep quality. Treatment regularly meets or exceeds the minimum clinically important differences defined for the respective instruments. Additional research is needed to further investigate effects on quality of life beyond improvements in daytime sleepiness and daytime functioning.
舌下神经刺激(HNS)最近被引入作为 OSA 患者的替代治疗方法。大量研究表明,通过减少呼吸事件并改善日间嗜睡和生活质量等症状,这种治疗方法可使 OSA 发生实质性变化。本综述的目的是进行系统评价和荟萃分析,以评估 HNS 治疗的患者报告结局和体验。
对 MEDLINE、Cochrane 和 Web of Science 进行系统文献检索,以确定报告不同 HNS 系统治疗 OSA 患者主观结局的随机对照和观察性研究。筛选了 406 篇文章的摘要,并对 55 篇文章进行了评估,以确定其是否符合入选标准。使用 ROBINS-I 工具评估偏倚风险。当确定有超过 2 项研究报告了特定结局的数据时,使用 RevMan 进行荟萃分析。
确定了 34 项发表的研究报告,涉及 3785 例患者,平均随访 11.8±12.2 个月,这些研究报告的数据被纳入荟萃分析。分析结果显示,ESS 问卷评估的日间嗜睡改善了 4.59 分(Z=42.82,p<0.001),FOSQ 评分评估的日间功能改善了 2.84 分(Z=28.38,p<0.001),PSQI 问卷评估的睡眠质量改善了 1.77 分(Z=2.53,p=0.010)。患者报告的体验始终是积极的,并从这一角度揭示了其他相关方面。
HNS 治疗可显著改善 OSA 患者的生活质量,并可靠地对日间嗜睡、日间功能和睡眠质量产生具有临床意义的影响。治疗通常符合或超过各自仪器定义的最小临床重要差异。需要进一步的研究来进一步调查改善日间嗜睡和日间功能以外的生活质量的影响。